Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, January 4, 2023
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
[ Wed, Jan 04th 2023
] - WOPRAI
Ed Arce Maintained (VERA) at Strong Buy with Decreased Target to $15 on, Jan 4th, 2023
Ed Arce of HC Wainwright & Co., Maintained "Vera Therapeutics, Inc." (VERA) at Strong Buy with Decreased Target from $36 to $15 on, Jan 4th, 2023.
Ed has made no other calls on VERA in the last 4 months.
There is 1 other peer that has a rating on VERA. Out of the 1 peers that are also analyzing VERA, 0 agree with Ed's Rating of Hold.
This is the rating of the analyst that currently disagrees with Ed
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $38 on, Friday, November 18th, 2022
